Kaitlyn D’Onofrio

DocwireNews

This week in the DocWire News rheumatology section, <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/dr-keenan-talks-about-pegloticase-in-uncontrolled-gout/">I interviewed Robert Keenan, MD</a>, an adjunct associate professor at Duke University School of Medicine, Division of Rheumatology and Immunology, and lead investigator on &ldquo;The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review,&rdquo; to discuss the study&rsquo;s findings.&ldquo;I think that this publication emphasizes that gout is not just a disease of intermittent flares, and it&rsquo;s important to recognize that these patients are kind of in a situation where the disease state has kind of gotten out of hand and it needs to be treated aggressively, and that it&rsquo;s important to treat these patients to target,&rdquo; Dr. Keenan said during our interview.<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/rituximab-increases-risk-of-severe-covid-19-in-patients-with-rheumatic-disease/">In COVID-19 news</a>, a study confirmed previous findings that determined a correlation between rituximab and increased risk for severe COVID-19. &ldquo;In particular, rituximab will have to be prescribed with particular caution in patients with inflammatory rheumatic and musculoskeletal diseases, especially if they have other comorbidities that render them particularly at risk of severe COVID-19 outcomes,&rdquo; the researchers wrote in their conclusion. The study appeared in&nbsp;<a href="https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00059-X/fulltext" target="_blank" rel="nofollow noopener noreferrer">The Lancet Rheumatology</a>.Finally, <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/upadacitinib-versus-adalimumab-how-do-these-arthritis-drugs-compare/">researchers compared upadacitinib versus adalimumab</a> and placebo in psoriatic arthritis. A low and high dose of upadacitinib were both superior to placebo, but only the higher dose outperformed adalimumab, the researchers discovered. &ldquo;The 30-mg dose but not the 15-mg dose was superior to adalimumab,&rdquo; they stated. The study was published in the&nbsp;<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2022516" target="_blank" rel="nofollow noopener noreferrer">New England Journal of Medicine</a>.In case you missed it:<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/dr-keenan-talks-about-pegloticase-in-uncontrolled-gout/">Dr. Keenan Talks About Pegloticase in Uncontrolled Gout</a><a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/rituximab-increases-risk-of-severe-covid-19-in-patients-with-rheumatic-disease/">Rituximab Increases Risk of Severe COVID-19 in Patients with Rheumatic Disease</a><a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/upadacitinib-versus-adalimumab-how-do-these-arthritis-drugs-compare/">Upadacitinib versus Adalimumab: How Do These Arthritis Drugs Compare?</a>

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Rheum Round-up: Interview with Dr. Keenan, Rixutimab Ups Severe COVID-19 Risk, PsA Drug Comparison

Rheumatology

This week in the DocWire News rheumatology section, I interviewed Robert Keenan, MD, an adjunct associate professor at Duke University School of Medicine, Division of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe